Developed by Shray Alag, The Harker School
Sections: Correlations,
Clinical Trials, and HPO
Navigate: Clinical Trials and HPO
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4012 | Thromboprophylaxis Wiki | 0.58 |
| drug3484 | SNO Wiki | 0.58 |
| drug4615 | non-RAS blocking antihypertensives Wiki | 0.58 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| drug4653 | placebo for clazakizumab Wiki | 0.58 |
| drug551 | Best standard of care Wiki | 0.58 |
| drug838 | Candesartan Wiki | 0.58 |
| drug2566 | Nitrogen gas Wiki | 0.41 |
| drug2041 | Ivermectin Pill Wiki | 0.41 |
| drug4256 | Vitamin Super B-Complex Wiki | 0.33 |
| drug2170 | Lopinavir/Ritonavir Wiki | 0.29 |
| drug3384 | Rivaroxaban Wiki | 0.26 |
| drug927 | Clazakizumab Wiki | 0.24 |
| drug2552 | Nitazoxanide Wiki | 0.15 |
| drug2916 | Placebo Wiki | 0.05 |
| Name (Synonyms) | Correlation | |
|---|---|---|
| D018352 | Coronavirus Infections NIH | 0.06 |
| D045169 | Severe Acute Respiratory Syndrome NIH | 0.02 |
| Name (Synonyms) | Correlation |
|---|
Navigate: Correlations HPO
There are 3 clinical trials
The study is a double-blind, randomised, placebo-controlled trial that will be conducted in healthcare settings and other facilities directly involved in COVID-19 case management. We will recruit healthcare workers and other staff working in a facility where there are cases of either proven, or suspected, COVID-19, who can be followed reliably for 5 months. 40,000 participants will be recruited and we predict an average of 400-800 participants per site in 50-100 sites. The participant will be randomised to receive either chloroquine or placebo (1:1 randomisation), or to hydroxychloroquine or placebo (1:1 randomisation). A loading dose of 10mg base/kg (four 155mg tablets for a 60kg subject), followed by 155 mg daily (250mg chloroquine phosphate salt/ 200mg hydroxychloroquine sulphate) will be taken for 3 months. If the participant is diagnosed with COVID-19, they will take continue to take the study medication until: - 90 days after enrolment (i.e., completion of kit) - hospitalised due to COVID-19 disease (i.e., not for quarantine purposes) in which case they will stop, or - advised to stop by their healthcare professional for other reasons Episodes of symptomatic respiratory illness, including symptomatic COVID-19, and clinical outcomes will be recorded in the Case Record Form during the follow-up period.
Description: Number of symptomatic COVID-19 infections will be compared between the chloroquine or hydroxychloroquine and placebo groups
Measure: Number of symptomatic COVID-19 infections Time: Approximately 90 daysDescription: Symptoms severity of COVID-19 will be compared between the two groups using a respiratory severity score.
Measure: Symptoms severity of COVID-19 Time: Approximately 90 daysDescription: Number of asymptomatic cases of COVID-19 will be determined by comparing serology in all participants at time of enrolment and at the end of follow up.
Measure: Number of asymptomatic cases of COVID-19 Time: Approximately 90 daysDescription: Number of symptomatic acute respiratory illnesses will be compared between the chloroquine or hydroxychloroquine and placebo groups.
Measure: Number of symptomatic acute respiratory illnesses Time: Approximately 90 daysDescription: Severity of symptomatic acute respiratory illnesses will be compared between the chloroquine or hydroxychloroquine and placebo groups.
Measure: Severity of symptomatic acute respiratory illnesses Time: Approximately 90 daysDescription: Genetic loci and levels of biochemical components will be correlated with frequency of COVID-19, Acute Respiratory Infection and disease severity.
Measure: Genetic loci and levels of biochemical components will be correlated with frequency of COVID-19, ARI and disease severity. Time: Approximately 90 daysDescription: Number of days lost to work in relation to the treatment arm
Measure: Assess the impact of chloroquine or hydroxychloroquine prophylaxis on number of days lost to work during the pandemic. Time: Approximately 90 daysDescription: The trial will collect data on monetary costs associated with the use of healthcare resources and determine the effects between treatment groups.
Measure: Assess the impact of chloroquine or hydroxychloroquine prophylaxis on healthcare costs Time: Approximately 90 daysDescription: The trial will collect data on health-related quality of life using the quality of life questionnaire (EQ-5D-3L) to determine the effects between treatment groups.
Measure: Assess the impact of chloroquine or hydroxychloroquine prophylaxis on quality of life measures using the quality of life questionnaire (EQ-5D-3L) Time: Approximately 90 daysThe Austrian Coronavirus Adaptive Clinical Trial (ACOVACT) is a randomized, controlled, multicenter, open-label basket trial that aims to compare various antiviral treatments for COVID-19. Moreover three substudies have been integrated. Currently, patients will be randomized to receive (hydroxy-)chloroquine, lopinavir/ritonavir or standard of care. Moreover, these patients are eligible for substudy A (randomized to rivaroxaban 5mg 1-0-1 vs. standard of care), substudy B (renin-angiotensin (RAS) blockade vs. no RAS blockade for patients with blood pressure >120/80mmHg), and substudy C (clazakizumab vs standard of care, for patients with respiratory deterioration and high inflammatory biomarkers). Endpoints were chosen based on the master protocol published by the World Health Organisation and include a 7-point scale of clinical performance, mortality, oxygen requirement (both dose and type), duration of hospitalization, viral load and safety.
Description: The primary endpoint is time to clinical improvement which is defined as time from randomization to an (sustained) improvement of at least one category on two consecutive days compared to the status at randomization measured on a seven-category ordinal scale (proposed by WHO). The 7-categories of the World Health Organization proposed scale, as follows: Not hospitalized, no limitations on activities Not hospitalized, limitation on activities; Hospitalized, not requiring supplemental oxygen; Hospitalized, requiring supplemental oxygen; Hospitalized, on non-invasive ventilation or high flow oxygen devices; Hospitalized, on invasive mechanical ventilation or ECMO; Death. During hospitalization this score will be determined daily (till day 29). If a patient is released from the hospital before day 29, the score will be determined at day 11 and 29 after randomization (depending when the patient was released or by telephone call).
Measure: sustained improvement (>48h) of one point on the WHO Scale Time: Inclusion to day 29, daily evaluationDescription: The scale described in the primary endpoint is used
Measure: Time to improvement on WHO Scale Time: Inclusion to day 29, daily evaluationDescription: The scale described in the primary endpoint is used
Measure: Mean change in the ranking on an ordinal scale from baseline Time: Inclusion to day 29, daily evaluationDescription: the National Early Warning Score includes respiratory rate, oxygen saturation, use of supplemental oxygen, temperature, systolic blood pressure, heart rate and levels of consciousness (AVPU Scale)
Measure: time to discharge or a National Early Warning Score (NEWS) ≤2 (maintained for 24h), whichever occurs first Time: Inclusion to day 29, daily evaluationDescription: The scale described in the primary endpoint is used
Measure: change from baseline in National Early Warning Score (NEWS) Time: Inclusion to day 29, daily evaluationDescription: new oxygen may include insufflation or oxygen mask, high flow oxygen devices, non-invasive ventilation devices or mechanical ventilation
Measure: Incidence of new oxygen use during the trial Time: Inclusion to day 29, daily evaluationDescription: number of days with requirement of mechanical ventilation
Measure: Ventilator free days until day 29 Time: Inclusion to day 29, daily evaluationDescription: obtained by polymerase chain reaction in nasal/oropharyngeal swabs, performed at baseline and then three times a week, if possible
Measure: Viral load/viral clearance Time: Inclusion to day 29, daily evaluationDescription: BMI (kg/m2), within all subjects the impact of obesity on overall mortality will be investigated
Measure: Obesity - mortality Time: BMI at admission, mortality until day 29Description: BMI (kg/m2) , within all subjects the impact of obesity on the duration of hospitalization will be investigated
Measure: Obesity - duration of hospitalization Time: BMI at admission, duration of hospitalization until day 29 or dischargeDescription: BMI (kg/m2) , within all subjects the impact of obesity on ICU admission will be investigated
Measure: Obesity - ICU admission Time: BMI at admission, ICU admission until day 29 or dischargeDescription: BMI (kg/m2) new oxygen may include insufflation or oxygen mask, high flow oxygen devices, non-invasive ventilation devices or mechanical ventilation
Measure: Obesity - new oxygen use Time: BMI at admission, new oxygen use until day 29 or dischargeDescription: lopinavir and ritonavir both interact with numerous other drugs by inhibiting the cytochrome enzymes 3A4. Using commercially available drug-interaction programs, the number and severity grading of drug-drug-interactions will be documented (for instance uptodate interaction tool, medscape). This is an exploratory analysis of drug-drug interactions with the above mentioned substances. severity grading usually encompass "contraindicated", "serious", "monitor closely", "minor" interaction.
Measure: Drug-drug interactions with lopinavir/ritonavir Time: Inclusion to day 29, daily evaluationDescription: for sub-study B only: RAS fingerprint measures metabolites involved in the renin-angiotensin-system. The influence of randomized treatment with candesartan (RAS blockade) will be analyzed
Measure: Renin Angiotensin System (RAS) fingerprint Time: Inclusion to day 29, daily evaluationChloroquine or hydroxychloroquine in COVID-19 treatment
Description: the number of patients with cure or death
Measure: Number of patients with cure or death Time: 1 monthAlphabetical listing of all HPO terms. Navigate: Correlations Clinical Trials
Data processed on September 26, 2020.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.
Drug Reports MeSH Reports HPO Reports